# Ofri Mosenzon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ofri-mosenzon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,236 |
| Field | Diabetes Treatment and Management |
| h-index | 56 |
| i10-index | 118 |
| Last Known Institution | Alzheimer's Association of Israel |
| OpenAlex ID | https://openalex.org/A5080475619 |
| ORCID iD | 0000-0002-5702-7584 |
| Works | 268 |

## Researcher papers

Showing 12 of 16.

- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus](https://scholariq.org/papers/saxagliptin-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-semaglutide-compared-with-liraglutide-and-placebo-for/)
- [Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus](https://scholariq.org/papers/comparison-of-the-effects-of-glucagon-like-peptide-receptor-agonists-and-sodium/)
- [Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial](https://scholariq.org/papers/heart-failure-saxagliptin-and-diabetes-mellitus-observations-from-the-savor-timi/)
- [Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial](https://scholariq.org/papers/effects-of-dapagliflozin-on-development-and-progression-of-kidney-disease-in/)
- [Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-heart-failure-and-mortality-in-type-2-diabetes/)
- [Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-atrial-fibrillation-in-patients-with-type-2-diabetes/)
- [Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-semaglutide-in-patients-with-type-2-diabetes-and/)
- [Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

## Researcher university

- [Alzheimer's Association of Israel](https://scholariq.org/institutions/alzheimer-s-association-of-israel/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.